NOVARTIS AG-SPONSORED ADR (NVS)
US66987V1098 - ADR
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.
Why Novartis Stock Topped the Market on Tuesday
A double beat on the latest quarterly results and raised guidance made investors happy.
Why Novartis Stock Topped the Market on Tuesday
A double beat on the latest quarterly results and raised guidance made investors happy.
NVS Stock Earnings: Novartis Beats EPS, Beats Revenue for Q1 2024
NVS stock results show that Novartis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Novartis Ag (NVS) Q1 2024 Earnings Call Transcript
NVS earnings call for the period ending March 31, 2024.
Jim Cramer shares his thoughts on RTX, Pepsi, Nucor, Novartis and Cadence Design Systems
During the Investing Club's Morning Meeting, Jim Cramer offered his thoughts on recent earnings from RTX, PepsiCo, Nucor, Novartis and Cadence Design Systems.
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
Compared to Estimates, Novartis (NVS) Q1 Earnings: A Look at Key Metrics
The headline numbers for Novartis (NVS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Novartis (NVS) comfortably beats first-quarter earnings and sales estimates. The company ups its outlook for 2024 on strong growth across key brands.
The Zacks Analyst Blog Highlights Novartis, American Express, ConocoPhillips, Netflix and Schlumberger
Novartis, American Express, ConocoPhillips, Netflix and Schlumberger are part of the Zacks top Analyst Blog.
Novartis Extends Three-Day Stock Sprint With First-Quarter Beat And Raise
Shares have risen markedly over the past two days and gained again Tuesday.
Stocks making the biggest premarket moves: General Motors, GE Aerospace, Novartis, JetBlue and more
These are the stocks posting the largest moves in the premarket.
Shares of Novartis climb 4.8% on raised guidance, better-than-expected results
Shares of Swiss drugmaker Novartis climbed 4.8% in early deals Tuesday after it raised its full-year guidance following better-than-expected first-quarter results.
Novartis Raises Forecast as Sales of New Blockbusters Climb
Novartis AG raised its forecast as sales of its blockbuster medicines for heart disease and psoriasis outpaced expectations.
Top Analyst Reports for Novartis, American Express & ConocoPhillips
Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), American Express Company (AXP) and ConocoPhillips (COP).
The Bad News Heading Into AbbVie's First-Quarter Earnings Report
AbbVie is working against numerous biosimilar versions of Humira. But one has "stepped up dramatically."
Novartis (NVS) to Report Q1 Earnings: What to Expect?
Novartis (NVS) key drugs Entresto, Kisqali and Pluvicto are likely to have fueled its top and bottom-line numbers in the first quarter.
Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS
Evaluate the expected performance of Novartis (NVS) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
These income stocks look like good options at current levels.
Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%.
Think globally with this high-yielding ETF.
Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%.
Think globally with this high-yielding ETF.
Arvinas inks over $1.0 billion deal with Novartis
Arvinas announces a licensing and asset sale transaction with Novartis. Arvinas stock is in the green today; Novartis is down nearly 1.0%.
Novartis wants to buy a German cancer drugmaker as it stops recruiting for its own trials
Just this week, the pharma giant slowed trials testing its blockbuster drug for early breast cancer
Novartis (NVS) to Undertake Job Cuts in Development Department
Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.